Merus (MRUS) Competitors $54.99 -0.63 (-1.13%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$55.02 +0.03 (+0.06%) As of 07/15/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, ASND, QGEN, BPMC, and BBIOShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Merus vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris Ascendis Pharma A/S QIAGEN Blueprint Medicines BridgeBio Pharma Intra-Cellular Therapies (NASDAQ:ITCI) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations. Does the media favor ITCI or MRUS? In the previous week, Merus had 10 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 11 mentions for Merus and 1 mentions for Intra-Cellular Therapies. Merus' average media sentiment score of 0.78 beat Intra-Cellular Therapies' score of 0.29 indicating that Merus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Merus 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in ITCI or MRUS? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 4.6% of Merus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, ITCI or MRUS? Intra-Cellular Therapies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Merus has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500. Is ITCI or MRUS more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Merus' net margin of -506.73%. Intra-Cellular Therapies' return on equity of -9.93% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Merus -506.73%-35.99%-29.83% Do analysts rate ITCI or MRUS? Intra-Cellular Therapies presently has a consensus price target of $109.70, indicating a potential downside of 16.81%. Merus has a consensus price target of $84.64, indicating a potential upside of 53.91%. Given Merus' stronger consensus rating and higher probable upside, analysts plainly believe Merus is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14 Which has preferable earnings & valuation, ITCI or MRUS? Intra-Cellular Therapies has higher revenue and earnings than Merus. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Merus$54.73M69.54-$215.33M-$4.08-13.48 SummaryMerus beats Intra-Cellular Therapies on 11 of the 17 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.85B$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-13.4820.2228.5419.58Price / Sales69.54298.23430.1194.56Price / CashN/A43.1536.0257.93Price / Book5.817.568.145.54Net Income-$215.33M-$55.11M$3.24B$257.73M7 Day Performance0.88%3.81%0.17%-0.08%1 Month Performance3.17%11.60%5.95%8.09%1 Year Performance-6.54%-2.11%26.22%13.02% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus1.9383 of 5 stars$54.99-1.1%$84.64+53.9%-5.4%$3.85B$54.73M-13.4837News CoverageITCIIntra-Cellular Therapies0.906 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9125 of 5 stars$20.52+1.1%$37.60+83.2%-20.3%$13.16B$3.12B11.662,682Positive NewsAnalyst RevisionRDYDr. Reddy's Laboratories2.7713 of 5 stars$15.08flat$16.95+12.4%-9.5%$12.59B$3.81B22.8527,811Positive NewsMRNAModerna4.2776 of 5 stars$29.90-1.9%$46.61+55.9%-74.0%$11.56B$3.24B-3.425,800Analyst ForecastAnalyst RevisionGap UpRGCRegencell Bioscience0.3405 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Positive NewsGap DownVTRSViatris2.9047 of 5 stars$9.20-1.3%$10.40+13.0%-18.8%$10.80B$14.74B-2.9032,000News CoverageASNDAscendis Pharma A/S3.7113 of 5 stars$175.98+1.0%$220.67+25.4%+27.5%$10.76B$393.54M-28.021,017Positive NewsQGENQIAGEN3.682 of 5 stars$47.49-1.8%$49.40+4.0%+16.7%$10.56B$1.98B119.075,765Positive NewsBPMCBlueprint Medicines1.0895 of 5 stars$128.40+0.0%$128.06-0.3%+8.2%$8.29B$508.82M-51.98640Positive NewsBBIOBridgeBio Pharma4.6361 of 5 stars$43.50-1.1%$58.85+35.3%+68.7%$8.26B$221.90M-12.32400Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Regencell Bioscience Competitors Viatris Competitors Ascendis Pharma A/S Competitors QIAGEN Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMajor Rollout of Social Security X?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
